Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Lucid Diagnostics Inc.

Get SEC filing alerts via email and in your feed for Lucid Diagnostics Inc.

LUCD

Lucid Diagnostics Inc.

Lucid Diagnostics Inc. is a medical diagnostics company focused on early detection of esophageal precancer and cancer in patients with gastroesophageal reflux disease (GERD). Its key products, EsoGuard and EsoCheck, offer non-invasive testing solutions. With a $60 billion market opportunity, Lucid targets 30 million at-risk U.S. individuals. The company is expanding access through partnerships and direct-to-consumer initiatives, addressing a vital need in cancer prevention.
This description was generated via AI from the most recent annual report. Updated 4 months ago.

Latest news & discussion for Lucid Diagnostics Inc.:

1
1
Lucid Diagnostics Inc. Lucid Diagnostics Reports $4.3 Million Revenue for Fiscal Year 2024, Faces $45.5 Million Net Loss

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Lucid Diagnostics Inc. Lucid Diagnostics Reports Revenue Growth, Narrowing Losses in Q3 2024

Via official filing (AI summary) | 6 months ago | 0 comments

3
1
Lucid Diagnostics Inc. Lucid Diagnostics Reports Revenue Growth to $976,000, Operating Loss of $11.19 Million for Q2 2024

Via official filing (AI summary) | 9 months ago | 0 comments

4
1
Lucid Diagnostics Inc. Lucid Diagnostics Reports 124% Revenue Increase to $1.0 Million in Q1 2024

Via official filing (AI summary) | 12 months ago | 0 comments

5
1
Lucid Diagnostics Inc. Lucid Diagnostics Reports Revenue Growth to $783,000 Despite Continued Operating Losses

Via official filing (AI summary) | over 1 year ago | 0 comments

6
1
Lucid Diagnostics Inc. Lucid Diagnostics Reports Q2 2023 Revenue of $159,000 and Net Loss of $11.4 Million

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Lucid Diagnostics Inc. Lucid Diagnostics Reports Revenue Growth to $446,000 but Incurred $16.2 Million Net Loss in Q1 2023

Via official filing (AI summary) | almost 2 years ago | 0 comments

8
1
Lucid Diagnostics Inc. Lucid Diagnostics Reports Significant Revenue Decline and Increased Losses in Q3 2022

Via official filing (AI summary) | over 2 years ago | 0 comments

9
1
Lucid Diagnostics Inc. Lucid Diagnostics Reports $14.6 Million Net Loss in Q2 2022, Revenue Increases to $189,000

Via official filing (AI summary) | over 2 years ago | 0 comments

10
1
Lucid Diagnostics Inc. Lucid Diagnostics Reports $189,000 Revenue and $12.3 Million Net Loss for Q1 2022

Via official filing (AI summary) | almost 3 years ago | 0 comments

11
1
Lucid Diagnostics Inc. Lucid Diagnostics Reports $200,000 Revenue in Q3 2021, Faces $6.96 Million Net Loss

Via official filing (AI summary) | over 3 years ago | 0 comments